Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer

Lung Cancer

Volumn 25, Issue 1, 1999, Pages 39-46

  Scagliotti, Giorgio V ^a   Crinó, Lucio ^d   Pozzi, Ernesto ^a   Corgna, Enrichetta ^b   Selvaggi, Giovanni ^a   Novello, Silvia ^a   Salsano, Giuseppe ^c   Gentile, Alfonso ^c   Palladino, Mariangela ^b   Marracolo, Francesca ^d   Tonato, Maurizio ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b Servizio di Radioterapia Oncologica   (Italy)

^c BRISTOL MYERS SQUIBB   (United States)

^d Medical Oncology Division   (Italy)

Author keywords

Carboplatin; Non small cell lung cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; GRANISETRON; ONDANSETRON; ORPHENADRINE; PACLITAXEL; PREDNISONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD CELL COUNT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0032801776     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00048-3     Document Type: Article

References (33)

1. Joss RA, Cavalli F, Goldrish A, et al. New agents in non-small cell lung cancer. Cancer Treat Rev 1984;11:205-37.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a mesa-analysis using update data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
3. Thatcher N, Anderson H, Betticher DC, Ranson M. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anti-Cancer Drugs 1995;6(Suppl 6):39-48.
4. Lillebaum RC, Green MR. Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J Clin Oncol 1993;11:1391-402.
5. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. A phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993;85:388-94.
6. Murphy WK, Fossella FV, Winn RJ, Shin DM, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993;85:384-7.
7. Gatzemeier U, Heckmayer M, Neahauss R, Schlauter I, et al. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase III trial. Semin Oncol 1995;22(Suppl 15):24-8.
8. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995;13:1609-14.
9. Alberola V, Rosell R, Gonzales-Larriba JL, Molina F, et al. Single agent taxol, 3-hour infusion, in untreated non-small cell lung cancer. Ann Oncol 1995;6(Suppl 3):S49-52.
10. Tester WJ, Jin PY, Reardon DH, Cohn JB, Cohen MH. Phase II study of patients with metastatic non-small cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer 1997;79:724-9.
11. Millward MJ, Bishop JF, Friedlander M, Levi JA, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 1996;14:142-8.
12. Sekine I, Nishiwaki Y, Watanabe K, Yoneda S, Saijo N. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res 1996;2:941-5.
13. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer. High-dose versus low dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
14. Rose CR. Taxol-based combination chemotherapy in vivo preclinical antitumour studies. Monogr J Natl Cancer Inst 1993;15:47-53.
15. Rowinsky EK, Chaudry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with G-CSF: neuromuscular toxicity is dose limiting. J Clin Oncol 1993;11:2010-20.
16. Johnson DH, Chang AY, Ettinger DS, Kim KM, Bonomi P. Recent advances with chemotherapy for NSCLC: the ECOG experience. Oncology 1998;12(1 Suppl 2):67-70.
17. Bonomi PD, Finkelstein DM, Rukdeschel JC, et al. Combination chemotherapy versus single agent followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602-13.
18. Vafai D, Israel V, Zaretsky S, Natale RB. Phase I/II trial of combination carboplatin and taxol in Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol (Abstr 1067) 1995;14:352.
19. National Cancer Institute. Investigator's Handbook. A manual for participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment. National Cancer Institute 1993:153-57.
20. Miller AB, Hoogstraten B, Staquet M, Winckler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
22. Belli L, Le Chevalier T, Goffried M, Adams D, et al. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results. Semin Oncol 1995;6(Suppl 15):29-33.
23. von Pawel J, Wagner H, Niederle N, Heider A, et al. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin Oncol 1996;6(Suppl 16):47-50.
24. Georgiadis MS, Schuler BS, Brown JE, Kieffer LV, et al. Paclitaxel by 96-hour continuous infusion in combination with cisplatin. A phase I trial in patients with advanced lung cancer. J Clin Oncol 1997;15:735-43.
25. Natale RB. A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study. Semin Oncol 1995;6(Suppl 15):34-7.
26. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 1995;13:1860-70.
27. Johnson DH, Paul DM, Hande KR, Shyr Y, et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 1996;14:2054-60.
28. Jagasia M, Johnson DH, Hande KR, Shyr Y, et al. Carboplatin and paclitaxel (1- and 24-hour infusion) in advanced non-small cell lung cancer: the results of sequential phase II trials. Proc Am Soc Clin Oncol (Abstr 1695) 1997;16:471a.
29. Bonomi P, Kim K, Chang A, Johnson D. Cisplatinletoposide vs paclitaxel/cisplatin/GCSF vs paclitaxel/cisplatin in non-small cell lung cancer. Oncology 1997;11(Suppl 3):9-10.
30. Giaccone G, Splinter TAW, De Brayne C, Kho GS, et al. Cisplatin/paclitaxel vs. cisplatin/teniposide for advanced non-small cell lung cancer. J Clin Oncol 1998;16:2133-41.
31. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlaw JL, Tan S, Wiltshaw E. Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;10:520-8.
32. Obassoju C, Johnson S, Rogatko A, et al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res 1996;2:549-52.
33. Belani CP, Natale RB, Lee JS, et al. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic nonsmall cell lung cancer. Proc Am Soc Clin Oncol (Abstr 1751) 1998;17:455a.